Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization

NCT02797704 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
6
Enrollment
OTHER
Sponsor class

Stopped the treatment was found to be inefficient for all recruited patients

Conditions

Interventions

Sponsor

Rabin Medical Center